DTU
DTU

Atorvastatin in Factorial with Omega-3 Fatty Acids Risk Reduction in Diabetes

Principal investigators:Rury Holman
Andrew Neil

Co-investigator:Andrew Farmer

Sponsor:Pfizer Ltd

Reference number:ISRCTN76737502

The Atorvastatin in Factorial with Omega-3 fatty acids Risk Reduction in Diabetes (AFORRD) study was a one-year, community-based, multi-centre, randomised controlled trial assessing the degree to which a statin and/or omega-3 fatty acids reduce the estimated risk of coronary heart disease (CHD) in 1,000 people with Type 2 diabetes.

Results

The results of the AFORRD trial were presented at the International Diabetes Federation Congress in Cape Town on Thursday 7th December 2006
[ Press release ]

News

AFORRD primary results published

09-Jan-2009
News Image

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
R. R....

[Read more...]

AFORRD results published online

13-Nov-2008
News Image

[Link]

AFORRD trial results

07-Dec-2006

The results of the AFORRD trial were presented at the International Diabetes Federation Congress in Cape Town on Thursday 7th December 2006.

[Link]


[News archive]